Patents by Inventor Suneel Gupta
Suneel Gupta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12370163Abstract: The invention is a method for treating levodopa naïve patients with Parkinson's disease by orally administering a controlled release levodopa formulation twice a day to the levodopa naïve patient and the method provides an improvement of a patient's motor state as determined by patient's Parkinson's disease diary, provides a reduction of from about 10%-40% in the patient's tremor, dyskinesia, and/or mobility and/or provides a reduction in the patient's Movement Disorders Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores by at least 3 points.Type: GrantFiled: January 15, 2025Date of Patent: July 29, 2025Assignee: Amneal Pharmaceuticals, LLCInventors: Richard D'Souza, Hester Visser, Suneel Gupta
-
Publication number: 20250152539Abstract: The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.Type: ApplicationFiled: January 15, 2025Publication date: May 15, 2025Applicant: Amneal Pharmaceuticals, LLCInventors: Richard D'Souza, Hester Visser, Suneel Gupta
-
Publication number: 20250152540Abstract: The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.Type: ApplicationFiled: January 15, 2025Publication date: May 15, 2025Applicant: Amneal Pharmaceuticals, LLCInventors: Richard D'Souza, Hester Visser, Suneel Gupta
-
Publication number: 20250152542Abstract: The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.Type: ApplicationFiled: January 15, 2025Publication date: May 15, 2025Applicant: Amneal Pharmaceuticals, LLCInventors: Richard D'Souza, Hester Visser, Suneel Gupta
-
Publication number: 20250152543Abstract: The invention is a method for treating levodopa naïve patients with Parkinson's disease by orally administering a controlled release levodopa formulation twice a day to the levodopa naïve patient and the method provides an improvement of a patient's motor state as determined by patient's Parkinson's disease diary, provides a reduction of from about 10%-40% in the patient's tremor, dyskinesia, and/or mobility and/or provides a reduction in the patient's Movement Disorders Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores by at least 3 points.Type: ApplicationFiled: January 15, 2025Publication date: May 15, 2025Applicant: Amneal Pharmaceuticals, LLCInventors: Richard D'Souza, Hester Visser, Suneel Gupta
-
Publication number: 20250152541Abstract: The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.Type: ApplicationFiled: January 15, 2025Publication date: May 15, 2025Applicant: Amneal Pharmaceuticals, LLCInventors: Richard D'Souza, Hester Visser, Suneel Gupta
-
Patent number: 12295931Abstract: The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.Type: GrantFiled: September 3, 2024Date of Patent: May 13, 2025Assignee: Amneal Pharmaceuticals, LLCInventors: Richard D'Souza, Hester Visser, Suneel Gupta
-
MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF
Publication number: 20250134818Abstract: The invention provides an oral solid formulation comprising (a) one or more controlled release components comprising a core comprising levodopa, esters or salts thereof and wherein the one or more controlled release components; and (b) one or more immediate release components comprising levodopa, esters or salts thereof. The oral solid formulation also contains a decarboxylase inhibitor and about 80% to 100% of the decarboxylase inhibitor present in the oral solid formulation is present in the one or more immediate release components.Type: ApplicationFiled: December 30, 2024Publication date: May 1, 2025Applicant: Impax Laboratories, LLCInventors: Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta -
Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof
Patent number: 12274793Abstract: The invention provides an oral solid formulation comprising (a) one or more controlled release components comprising a core comprising levodopa, esters or salts thereof and wherein the one or more controlled release components; and (b) one or more immediate release components comprising levodopa, esters or salts thereof. The oral solid formulation also contains a decarboxylase inhibitor and about 80% to 100% of the decarboxylase inhibitor present in the oral solid formulation is present in the one or more immediate release components.Type: GrantFiled: October 10, 2024Date of Patent: April 15, 2025Assignee: Impax Laboratories, LLCInventors: Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta -
Patent number: 12263148Abstract: The invention is a method for treating patients with Parkinson's disease, primary parkinsonism/idiopathic parkinsonism, post-encephalitic parkinsonism, parkinsonism that may follow carbon monoxide intoxication, or parkinsonism that may follow manganese intoxication and provides an improvement of a patient's total post-dose “On” time or “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.Type: GrantFiled: August 13, 2024Date of Patent: April 1, 2025Assignee: Amneal Pharmaceuticals, LLCInventors: Richard D'Souza, Hester Visser, Suneel Gupta
-
Patent number: 12263149Abstract: The invention is a method for treating patients with Parkinson's disease, primary parkinsonism/idiopathic parkinsonism, post-encephalitic parkinsonism, parkinsonism that may follow carbon monoxide intoxication, or parkinsonism that may follow manganese intoxication and provides an improvement of a patient's total post-dose “Off” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.Type: GrantFiled: August 28, 2024Date of Patent: April 1, 2025Assignee: Amneal Pharmaceuticals, LLCInventors: Richard D′Souza, Hester Visser, Suneel Gupta
-
MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF
Publication number: 20250099389Abstract: The invention provides an oral solid formulation comprising (a) one or more controlled release components comprising a core comprising levodopa; and (b) one or more immediate release components comprising levodopa. The oral solid formulation also contains a decarboxylase inhibitor wherein the one or more controlled release components are substantially free of the decarboxylase inhibitor.Type: ApplicationFiled: December 10, 2024Publication date: March 27, 2025Applicant: Impax Laboratories, LLCInventors: Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta -
MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF
Publication number: 20250032421Abstract: The invention provides an oral solid formulation comprising (a) one or more controlled release components comprising a core comprising levodopa, esters or salts thereof and wherein the one or more controlled release components; and (b) one or more immediate release components comprising levodopa, esters or salts thereof. The oral solid formulation also contains a decarboxylase inhibitor and about 80% to 100% of the decarboxylase inhibitor present in the oral solid formulation is present in the one or more immediate release components.Type: ApplicationFiled: October 10, 2024Publication date: January 30, 2025Applicant: Impax Laboratories, LLCInventors: Ann Hsu, Liang Dong, Amy Dong, Suneel Gupta -
Patent number: 12201596Abstract: The invention is a method for treating patients with post-encephalitic parkinsonism, parkinsonism that may follow carbon monoxide intoxication, or parkinsonism that may follow manganese intoxication by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.Type: GrantFiled: September 3, 2024Date of Patent: January 21, 2025Assignee: Amneal Pharmaceuticals, LLCInventors: Richard D'Souza, Hester Visser, Suneel Gupta
-
Patent number: 12194150Abstract: The invention provides oral dosing regimens of controlled release levodopa compositions for use in treating patients with Parkinson's disease.Type: GrantFiled: December 21, 2021Date of Patent: January 14, 2025Assignee: Amneal Pharmaceuticals LLCInventors: Richard D'Souza, Hester Visser, Suneel Gupta
-
Publication number: 20250000831Abstract: The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.Type: ApplicationFiled: September 3, 2024Publication date: January 2, 2025Applicant: Amneal Pharmaceuticals, LLCInventors: Richard D'Souza, Hester Visser, Suneel Gupta
-
Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof
Patent number: 12178919Abstract: The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a muco-adhesive coating and the muco-adhesive coating is externally coated with an enteric coating; and (b) an immediate release component comprising levodopa. The invention further provides a method for making and using the oral solid formulation.Type: GrantFiled: August 1, 2024Date of Patent: December 31, 2024Assignee: Impax Laboratories, LLCInventors: Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta -
Patent number: 12178918Abstract: The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a muco-adhesive coating and the muco-adhesive coating is externally coated with an enteric coating; and (b) an immediate release component comprising levodopa. The invention further provides a method for making and using the oral solid formulation.Type: GrantFiled: June 26, 2024Date of Patent: December 31, 2024Assignee: Impax Laboratories, LLCInventors: Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
-
Publication number: 20240423940Abstract: The invention is a method for treating patients with post-encephalitic parkinsonism, parkinsonism that may follow carbon monoxide intoxication, or parkinsonism that may follow manganese intoxication by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.Type: ApplicationFiled: September 3, 2024Publication date: December 26, 2024Applicant: Amneal Pharmaceuticals, LLCInventors: Richard D'Souza, Hester Visser, Suneel Gupta
-
Publication number: 20240423939Abstract: The invention is a method for treating patients with Parkinson's disease, primary parkinsonism/idiopathic parkinsonism, post-encephalitic parkinsonism, parkinsonism that may follow carbon monoxide intoxication, or parkinsonism that may follow manganese intoxication and provides an improvement of a patient's total post-dose “Off” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.Type: ApplicationFiled: August 28, 2024Publication date: December 26, 2024Applicant: Amneal Pharmaceuticals, LLCInventors: Richard D'Souza, Hester Visser, Suneel Gupta